Peng, Cheng-Yuan

Publishing since 1999 (Senior)

Has published 38 publications in 12 years

Number of publications published per year by Peng, Cheng-Yuan. (Source : PubMed)

Distribution of publications types for Peng, Cheng-Yuan. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Peng CY, Pan SL, Pai HC, Tsai AC, Guh JH, Chang YL, Kuo SC, Lee FY, Teng CM. THE INDAZOLE DERIVATIVE YD-3 SPECIFICALLY INHIBITS THROMBIN-INDUCED ANGIOGENESIS IN VITRO AND IN VIVO.  Shock  2010  
•  Liu YN, Pan SL, Peng CY, Huang DY, Guh JH, Chen CC, Shen CC, Teng CM. Moscatilin repressed lipopolysaccharide-induced HIF-1alpha accumulation and NF-kappaB activation in murine RAW264.7 cells.  Shock  2010;33;1  
•  Lee CH, Yang SF, Peng CY, Li RN, Chen YC, Chan TF, Tsai EM, Kuo FC, Huang JJ, Tsai HT, Hung YH, Huang HL, Tsai S, Wu MT. The precancerous effect of emitted cooking oil fumes on precursor lesions of cervical cancer.  Int. J. Cancer  2009  
•  Lai HC, Tsai CC, Feng CL, Yu CJ, Chou JW, Huang WH, Hsu CH, Cheng KS, Peng CY. Epigastric pain in a man with previous subtotal gastrectomy.  Gut  2009;58;10  
•  Yu CJ, Wang HH, Chou JW, Lai HC, Huang WH, Peng CY, Cheng KS, Chen YF. Phlebosclerotic colitis with nonsurgical treatment.  Int J Colorectal Dis  2009;24;10  
•  Liu YN, Pan SL, Liao CH, Huang DY, Guh JH, Peng CY, Chang YL, Teng CM. Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7.  Shock  2009;32;3  
•  Al-Zubairi AS, Abdul AB, Abdelwahab SI, Peng CY, Mohan S, Elhassan MM. Eleucine indica Possesses Antioxidant, Antibacterial and Cytotoxic Properties.  Evid Based Complement Alternat Med  2009  
•  Chainuvati S, Cheng J, Hou JL, Hsu CW, Jia JD, Komolmit P, Kwon SY, Lee CH, Li H, Li Y, Liu CJ, Neo BL, Peng CY, Tanwandee T, Wongcharatrawee S, Wu JC, Yu ML, Zhang XX. Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand.  Hepatology international  2009  
•  Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage.  J. Hepatol.  2009;50;5  
•  Su WP, Peng CY, Lai HC, Liao KF, Huang WH, Chuang PH, Chen CB, Jeng LB. Persistent transaminase elevations in chronic hepatitis C patients with virological response during peginterferon and ribavirin therapy.  Hepatogastroenterology  2009;56;91-92  

[ See timeline ] [ See all publications ]